Takeda Pharmaceutical (TAK) Receivables - Other (2018 - 2026)

Takeda Pharmaceutical's Receivables - Other history runs 9 years deep, the most recent figure standing at $231.4 million for Q1 2026.

• On a quarterly basis, Receivables - Other fell 39.19% year-over-year to $231.4 million in Q1 2026; TTM through Mar 2026 was $231.4 million, a 39.19% decrease from a year earlier, with the FY2026 full-year figure at $241.1 million, down 36.74% from the prior year.
• Receivables - Other slipped to $231.4 million in Q1 2026 per TAK's latest filing, from $380.5 million in the prior quarter.
• Across five years, Receivables - Other topped out at $680.9 million in Q1 2022 and bottomed at $231.4 million in Q1 2026.
• The 5-year median for Receivables - Other is $380.5 million (2025), against an average of $446.0 million.
• Across the five-year window, Receivables - Other climbed 0.76% in 2025 and slumped 39.19% in 2026, its largest moves.
• Year by year, Receivables - Other stood at $680.9 million in 2022, then decreased by 17.84% to $559.4 million in 2023, then sank by 32.5% to $377.6 million in 2024, then advanced by 0.76% to $380.5 million in 2025, then slumped by 39.19% to $231.4 million in 2026.
• Per Business Quant, the three latest TAK Receivables - Other figures stand at $231.4 million (Q1 2026), $380.5 million (Q1 2025), and $377.6 million (Q1 2024).